

The substrate of the biopsychosocial influences in the carcinogenesis of the digestive tract

^{1,2}Georgică C. Târtea, ^{1,2}Cristina Florescu, ^{1,3}Daniel Pirici, ^{1,4}Daniel Caragea, ^{1,5}Elena A. Târtea, ^{1,6}Cristin C. Vere

¹University of Medicine and Pharmacy of Craiova; ²Department of Cardiology; ³Department of Pathology; ⁴Department of Nephrology; ⁵Department of Neurology; ⁶Department of Gastroenterology and Hepatology

Abstract

Digestive cancer represents a severe public health problem, being one of the main causes of death. It is considered a multifactorial disease, with hereditary predisposition, environmental factors, and other factors involved in carcinogenesis. Both the evolution and the pathogenesis of digestive neoplasms remain incompletely elucidated. As a multifactorial disease, it can be approached by taking into account the biopsychosocial influences via enteric nervous system. Many peptides and non-peptides having a neurotransmitter role can be found in the enteric nervous system, which can influence the neoplastic process directly or indirectly by affecting some angiogenic, growth, and metastasis factors. However, neurotransmitters can also cause directly, through intercellular signaling, the angiogenesis, the proliferation, and the digestive neoplasms' metastasis. This new approach to neoplasms of the digestive tube assumes broader psychosocial factors can play an important role in the understanding the ethiopathogenic, the evolution of the disease, and determination of possible molecular targeted therapies; it also suggests that behavioral strategies may be important for maintaining a healthy state with respect to the digestive tract.

Keywords: enteric nervous system, neurotransmitters, carcinogenesis, biopsychosocial influences



Corresponding author: Dr. Georgică C. Târtea, University of Medicine and Pharmacy of Craiova
e-mail: georgetarte@gmail.com

Introduction

Digestive cancer represents a serious public health problem. Epidemiologically 20% of the cancers involve the digestive tract, and this represents over 25% of the deaths caused by cancer (1). Digestive cancer is considered a multifactorial disease, with hereditary predisposition, environmental factors and other factors involved in carcinogenesis. Both the evolution and the pathogenesis of digestive neoplasms remain incompletely elucidated.

On the other hand, currently there is a trend of replacing the disease's classic etiological pattern with a view that assumes a biopsychosocial approach. Although the idea of the mind playing a role in the etiology of diseases was initially marginalized, Western medicine is increasingly viewing the mind and the body as linked within an integrated system, the disorder of which causes pain (the way a person detects changes in his health condition) and disease (2). According to biopsychosocial view, symptoms, despite the fact they can have a multiple pathophysiological determinism, can be affected by both the sociocultural and psychological influences (3). This idea is not new: the approach of making connections between the psychological influences and cancer originates from the Greek doctor Galen, who in the I an century before Christ observed that

so called melancholic women developed breast cancer more frequently than those with the other behavioral types (4).

Many studies have described both the involvement of the nervous system in the modulation of tumor progression and the possible signaling mechanisms from tumors to nervous system (5,6,7). Despite this, much remains unexplained. Here we attempt to highlight some of the interactions between the central nervous system and digestive tract carcinogenesis. This new way of understanding the initiation, progression and tumor metastasis, represents in biopsychosocial terms, a new way to approach and manage the disease. This paper attempts to demonstrate the pathophysiologic substrate which is under the influence of the nervous system, the center of all mental activities/processes.

Discussion

Brain-gastrointestinal tract axis

The gastrointestinal tract has its own nervous system called the enteric nervous system. This system is entirely disposed in the intestinal wall, starting from the esophagus to the anus. About 100 million neurons are part of the enteric nervous system, almost the same number as in the spinal cord (8). However, there are also other neuronal networks which control the digestive functions, networks that are ordered in four main levels of

integrative organization (2). If the first level is represented by the enteric nervous system, the second level is the paraspinal sympathetic ganglia, where peripheral reflex arcs are influenced by sympathetic preganglionic fibers, which originate from the spinal cord. The next two levels are part of the central nervous system. At the third level, sympathetic and parasympathetic efferents towards the intestine are caused, at least partially, by reflexes with the afferent arc represented by sensory fibers which follow the path of autonomous nerves. The fourth level is represented by superior nervous centers that generate descendant signals, which are integrated with the sensory afferent signals at the third level (9).

Neurotransmitters and digestive cancer

Many peptides and non-peptides having a neurotransmitter role are found in the enteric nervous system (10). Recent studies using immunohistochemical methods have identified neurotransmitters for some neurons in gastrointestinal tract, their presence or their absence representing a method of classifying the enteric neurons (11). In attempt to deepen the understanding of the multiple functions of the enteric nervous system, researchers worldwide have identified more than twelve substances acting as neurotransmitters, substances that are being released from the different enteric neurons endings (8). Among these are: acetylcholine, norepinephrine, adenosine triphosphate, serotonin,

dopamine, cholecystokinin, P substance, vasoactive intestinal polypeptide, somatostatin, leu-enkephalin, met-enkephalin and bombesin. The actions of many of these are not sufficiently well known (8).

Due to the link between nervous elements and blood vessels in tumor tissues, and to the influence of certain neurotransmitters on tumor cells, some authors refer to a neuro-neoplastic synapse (12,13,14). Via some neurotransmitters, locally released stimulating or inhibitory influences over the activity of neoplastic cells may exist. On the other hand, changing the balance between stimulating and inhibitory neurotransmitters can confirm this assumption (15).

The influence of neurotransmitters on the neoplastic process can be exercised directly or indirectly by affecting elements of angiogenic, growth and metastasis factors. But neurotransmitters can cause directly, through intercellular signaling, the angiogenesis, the proliferation and the digestive neoplasm's metastasis (15).

In vitro studies show that norepinephrine, dopamine and P substance increase the proliferation rate of cells in colon neoplasm (12,16). Catecholamines act on the digestive system by stimulating beta-adrenergic receptors. This binding is responsible for the activation of adenylate cyclase via G_s protein, which is responsible for the increasing the intracellular concentration of AMPc (17). This acts like a signal or second messenger

transducer which changes, in turn, the percentage of several enzyme-catalyzed reactions. The final result is represented by the upregulation of angiogenic factors (18,19).

Angiogenesis is a complex process that includes several stages, each having an important role in the progression and metastasis of digestive neoplasms (20). Several factors initiate and sustain this process: VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), aFGF (acidic fibroblast growth factor), PDGF (platelet-derived growth factor), HGF (hepatocyte growth factor), Ang-1 (angiopoietin-1), but also other factors which can be involved in the angiogenesis cascade (21). The most important factor is VEGF, with many studies indicating an overexpression of the vascular endothelial factor, which appears after the stimulation of beta2 adrenergic receptors (22-26).

Metalloproteinases represent another protein group with enzymatic activity which leads to the progression and metastasis of digestive neoplasms (27). Their primary role is to degrade the tissue from the tumoral microenvironment that allows, on one hand, tumoral progression and, on the other hand, remodeling tissues among blood vessels (28,29). Their level, as well as the level of VEGF, can be increased by stimulating beta-adrenergic receptors (17).

On the other hand, acetylcholine can cause directly or indirectly, the overexpression of some growth, angiogenic and proliferation factors in neoplastic cells (30,31,32). Noteworthy is that acetylcholine, by activating M3 muscarinic receptors and by stimulating metalloproteinase-7 (MMP-7), can cleave heparin binding epidermal growth factor receptors (HB-EGF) from Pro-HB-EGF (33). A way of intercellular signaling is thus activated which results in the transcription of some genes responsible for uncontrolled proliferation and of the avoidance of apoptosis by neoplastic cells (34,35,36).

Besides the neurotransmitters mentioned above, others are also found. Several studies show that surgical or chemical denervation of different segments of the digestive tract negatively influence carcinogenesis at that level (37,38).

Psychological factors and neoplasm

Many neurotransmitters implicated in carcinogenesis are also associated with negative psychological factors, which themselves may be relevant factors for the patient's health. The past decades have been characterized by a progressing interest regarding stress' effects over the gastrointestinal tract, as explored in both human and animal studies (39). In rodents, stress affects hydric homeostasis and natural defense barriers, and it increases the permeability of mucous, allowing their penetration by bacteria (40). Clinical studies

show that negative psychological factors affect the onset, promotion, progression, and metastasis of tumors (41). Studies also show that through sympathetic nervous mechanisms and through the chronic activation of hypothalamic-pituitary-adrenal axis, the immune response is affected. In this way, deficiencies in the DNA repairing mechanisms appear, with the alteration of the function of some important genes implicated in cellular replication and in apoptosis (42). It has been observed that drugs such as adrenergic system blockers or prostaglandins reduce the effects mediated by stress in carcinogenesis (43).

Brain-mast cell axis in malignant tumors of digestive tract

Currently, the connection between brain and mast cell provides a more plausible mechanism to explain the evident relation between stress and defining symptoms of irritable bowel syndrome (2). Inflammatory mediators released by these cells access and influence ENS, via paracrine changes of electric and synaptic behavior of enteric neurons (44). Evidence of brain-mast cell connection is offered by the Pavlovian conditioning possibility of mast cells degranulation (45). The influence of the CNS over the mast cells from the superior digestive tract is also suggested by the increasing concentration of histamine at their level when the vagus nerve is being stimulated (46). Electrical stimulation of spinal afferents in the small intestine

causes histamine releasing from mast cells, an effect mediated by P substance's action on neurokinin-1receptor, which is being expressed on the surface of mast cells (47, 48).

Studies have also demonstrated that mast cells play an important role in carcinogenesis by releasing inflammatory cytokines which affect tumor progression, angiogenesis, and metastasis (49). In 2009, research suggested that mast cells can be the target of neoplastic therapy (50). More recently in 2010, the infiltration of pancreatic tumors with mast cells has been associated with a poor prognosis (51). Another study performed in the same year showed that gastric cancer malignity is correlated with tumor and peritumoral infiltration degree with mast cells (52).

Conclusions

Cancer of the digestive tube represents one of the major problems currently facing society. This multifactorial disease and may be best studied by taking into account the biopsychosocial influences via enteric nervous system. The enteric nervous system is permanently linked not only with the central nervous system, but also with the other neuronal networks such as sympathetic and parasympathetic autonomic nervous system.

Influences of the central nervous system (both those sociocultural and psychological) can be reflected in the carcinogenesis process through both

the interaction with the enteric nervous system and through mast cells. This new approach to neoplasms of the digestive tube plays an important role in the understanding the etiopathogenesis, the evolution of the disease, determination of possible molecular targeted therapies and also determination of some behavioral cues for sustaining good health status.

Acknowledgments

All authors equally contributed in the research and drafting of this paper.

References

1. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Taché Y, Wood JD. Fundamentals of neurogastroenterology: basic science. *Gastroenterology* 2006; 130(5): 1391-411.
2. Thomas H. Neurogastroenterology: A window on the ENS. *Nat Rev Gastroenterol Hepatol.* 2016; 13(8): 436-7.
3. Novack DH, Cameron O, Epel E, Ader R, Waldstein SR, Levenstein S, Antoni MH, Wainer AR. Psychosomatic medicine: the scientific foundation of the biopsychosocial model. *Acad Psychiatry* 2007; 31(5): 388-401.
4. Fife A, Beasley PJ, and Fertig DL. Psychoneuroimmunology and cancer: historical perspectives and current research. *Adv neuroimmunol.* 1996; 6(2): 179-190.
5. Gidron Y, Perry H, Glennie M. Does the vagus nerve inform the brain about preclinical tumours and modulate them? *Lancet Oncol.* 2005; 6(4): 245-248.
6. Mravec B, Gidron Y, Hulin I. Neurobiology of cancer: Interactions between nervous, endocrine and immune systems as a base for monitoring and modulating the tumorigenesis by the brain. *Semin Cancer Biol.* 2008; 18(3): 150- 63.
7. Ondicova K, Mravec B. Role of nervous system in cancer aetiopathogenesis. *Lancet Oncol.* 2010; 11(6): 596-601.
8. Hall, John E. Guyton and Hall textbook of medical physiology. *Elsevier Health Sciences,* 2010.
9. Arina P. The brain-gut interaction: the conversation and the implications. *South African Journal of Clinical Nutrition* 2011; 24(3): S8-S14.
10. Ray K. Neurogastroenterology: A tale of two neurons - distinct functions of vagal afferents of the gut. *Nat Rev Gastroenterol Hepatol.* 2016; 13(8): 435.
11. Wood JD, Alpers DH, Andrews PL. *Fundamentals of neurogastroenterology.* Gut 1999; 4(2): II6-II16.
12. Entschladen F, Palm D, Niggemann B, Zaenker KS. The cancer's nervous tooth: Considering the neuronal crosstalk within tumors. *Semin Cancer Biol.* 2008; 18(3): 171- 5.
13. Matsushita M, Masaoka T, Suzuki H. Emerging treatments in neurogastroenterology: Acotiamad, a novel treatment option for functional

- dyspepsia. *Neurogastroenterol Motil.* 2016; 28(5): 631-8.
14. Zänker KS. The neuro-neoplastic synapse: does it exist? *Prog Exp Tumor Res* 2007; 39: 154-161.
15. Schuller, Hildegard M. Neurotransmission and cancer: implications for prevention and therapy. *Anti-cancer Drugs* 2008; 19(7): 655-671.
16. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. *Lancet Oncol.* 2004; 5(4): 254-258.
17. Fitzgerald PJ. Is norepinephrine an etiological factor in some types of cancer? *Int J Cancer* 2009; 124(2): 257- 263.
18. Ray K. Neurogastroenterology: Enteric neurons and macrophage crosstalk. *Nat Rev Gastroenterol Hepatol.* 2016; 13(3): 123.
19. Shi M, Yang Z, Hu M, Liu D, Hu Y, Qian L, Zhang W, Chen H, Guo L, Yu M, Song L, Ma Y, Guo N. Catecholamine-Induced β 2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. *Journal Immunol.* 2013; 190(11): 5600-8.
20. Lee JY, Kim N, Kim GH, Kim GH. Comparing the Areas of Interest in the Field of Functional Gastrointestinal Disorder and Neurogastroenterology and Motility between the East and the West. *J Neurogastroenterol Motil.* 2015; 21(4): 503-10.
21. Jarmuż A, Zielińska M, Storr M, Fichna J. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. *Neurogastroenterol Motil.* 2015; 27(8): 1057-68.
22. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nat Med.* 2006; 12(8): 939- 944.
23. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. *Clinical Cancer Research* 2009; 15(8): 2695- 2702.
24. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R. Norepinephrine up-regulates the expression of

- vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. *Cancer Res.* 2006; 66(21): 10357-64.
25. Vilardi BM, Bravo-Calderon DM, Bernabe DG, Oliveira SH, Oliveira DT. VEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors. *Tumour Biol* 2013; 34(1): 139–43.
 26. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. *Brain Behav Immun.* 2009; 23(2): 267-275.
 27. Verma S, Kesh K, Ganguly N, Jana S, Swarnakar S. Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidants. *World J Biol Chem.* 2014; 5(3): 355-376.
 28. Goebel-Stengel M, Mazzuoli-Weber G, Demir IE, Wouters MM, Gourcerol G, Stengel A. TANDEM - a novel concept to bring basic and clinical scientists together in order to push borders in Neurogastroenterology & Motility. *Neurogastroenterol Motil.* 2015; 27(10): 1515-8.
 29. Langers AM, Verspaget HW, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ, Hardwick JC, Hommes DW, Sier CF. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. *Br J Cancer* 2012; 106(9): 1495-98.
 30. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? *Nat Rev Cancer* 2009; 9(3): 195-205.
 31. Tracey, Kevin J. Reflex control of immunity. *Nat Rev Immunol.* 2009; 9(6): 418-28.
 32. Al-Wadei HA, Schuller HM. Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. *Journal Pathol.* 2009; 218(4): 437-45.
 33. Von Rosenvinge, EC, Raufman JP. Muscarinic receptor signaling in colon cancer. *Cancers (Basel)* 2011; 3(1): 971-81.
 34. Xie G, Cheng K, Shant J, Raufman JP. Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. *Am J Physiol Gastrointest Liver Physiol.* 2009; 296(4): G755-G763.
 35. Cheng K, Xie G, Khurana S, Heath J, Drachenberg CB, Timmons J, Shah N, Raufman JP. Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and

- zinc finger protein 277 expression in colon neoplasia. *Mol Cancer* 2014; 13(1): 77.
36. Shah N, Khurana S, Cheng K, Raufman JP. Muscarinic receptors and ligands in cancer. *Am J Physiol Cell Physiol* 2009; 296(2): C221-C232.
37. Zhao CM, Hayakawa Y, Kodama Y, Muthupalani S, Westphalen CB, Andersen GT, Flatberg A, Johannessen H, Friedman RA, Renz BW, Sandvik AK, Beisvag V, Tomita H, Hara A, Quante M, Li Z, Gershon MD, Kaneko K, Fox JG, Wang TC, Chen D. Denervation suppresses gastric tumorigenesis. *Sci Transl Med.* 2014; 6(250): 250ra115.
38. Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H. Nerve–Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression. *Cancer Res.* 2015; 75(9): 1777-1781.
39. Ochoa-Cortes F, Turco F, Linan-Rico A, Soghomonyan S, Whitaker E, Wehner S, Cuomo R, Christofi FL. Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases. *Inflamm Bowel Dis.* 2016; 22(2): 433-49.
40. Velin AK, Ericson AC, Braaf Y, Wallon C, Söderholm JD. Increased antigen and bacterial uptake in follicle associated epithelium induced by chronic psychological stress in rats. *Gut.* 2004; 53(4): 494-500.
41. Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. *Brain Behav Immun.* 2009; 23(1): 10-15.
42. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. *Lancet Oncol.* 2004; 5(10): 617-625.
43. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, Ben-Eliyahu S. Perioperative use of β -blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. *Ann Surg Oncol.* 2008; 15(7): 2042-2052.
44. Liu S, Hu HZ, Gao N, Gao C, Wang G, Wang X, Peck OC, Kim G, Gao X, Xia Y, Wood JD. Neuroimmune interactions in guinea pig stomach and small intestine. *Am J Physiol Gastrointest Liver Physiol.* 2003; 284(1): G154-G164.
45. Saperas E, Nogueiras C, Mourelle M, Antolín M, Cadahia A, Malagelada JR. Release of mast cell mediators into the jejunum by cold pain stress in humans. *Gastroenterology* 1998; 114(4): 640-648.
46. Broaddus RR, Castro GA. Mast cell-mediated colonic immune function and its inhibition by dietary aspirin in mice infected with *Trichinella spiralis*. *Int Arch Allergy Immunol.* 1994; 105(2): 135-142.

47. Santos J, Saperas E, Mourelle M, Antolín M, Malagelada JR. Regulation of intestinal mast cells and luminal protein release by cerebral thyrotropin-releasing hormone in rats. *Gastroenterology* 1996; 111(6): 1465-73.
48. Conti Pio, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tetè S, Mastrangelo F, Perrella A, De Lutiis MA, Tagen M, Theoharides TC. Role of mast cells in tumor growth. *Ann Clin Lab Sci.* 2007; 37(4): 315-22.
49. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor micro-environment. *Blood* 2008; 112(4): 1269-79.
50. Ribatti D, Crivellato E. The controversial role of mast cells in tumor growth. *Int Rev Cell Mol Biol.* 2009; 275: 89-131.
51. Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, Dangi-Garimella S, Wang E, Munshi HG, Khazaie K, Bentrem DJ. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. *Clin Cancer Res.* 2010; 16(8): 2257-2265.
52. Ribatti D, Guidolin D, Marzullo A, Nico B, Annese T, Benagiano V, Crivellato E. Mast cells and angiogenesis in gastric carcinoma. *Int. J Exp Pathol.* 2010; 91(4): 350-356.